Abstract：Objective To explore the clinical effect of Octreotide in the adjuvant treatment of mild acute pancreatitis.Methods A total of 96 patients with mild acute pancreatitis admitted to our hospital from January 2017 to September 2018 were enrolled in the study.They were divided into the control group and the study groups according to random number table method，48 cases in each group.The patients in the control group were treated with Ulinastatin，the patients in the study group were treated with adjuvant Octreotide.The clinical efficacy，the level of interleukin-1 （IL-1），interleukin-6（IL-6），interleukin-10（IL-10），interleukin-12（IL-12），superoxide dismutase（SOD），malondialdehyde（MDA），and adverse reactions were compared between the two groups.Results The clinical total effective rate of the study group（93.75%）was higher than that of the control group（79.17%）（P＜0.05）.There were no significant differences in the level of IL-1，TL-6，IL-10，IL-12，SOD and MDA between the two groups before intervention （P＞0.05）.After intervention，the levels of IL-1，TL-6，IL-10，IL-12 and MDA in both groups were lower than those before intervention，and the SOD level was higher than that before intervention（P＜0.05）.After intervention，the SOD level of the study group was higher than that of the control group，and the levels of IL-1，TL-6，IL-10，IL-12 and MDA of the study group were lower than those of the control group （P＜0.05）.There was no significant difference in the incidence of adverse reactions between the study group（6.25%）and the control group（4.17%）（P＞0.05）.Conclusion Octreotide-assisted Ulinastatin is effective in the treatment of mild acute pancreatitis，which can significantly reduce the inflammatory response and improve the level of oxidative stress.
京公网安备 11010502046607号